Even Eeyore would join this stockmarket party
US investors are the most bullish than they have been in two decades, with America’s S&P 500 reaching a new-all time high last Friday.
US investors are the most bullish than they have been in two decades, report Rita Nazareth and Claire Ballentine for Bloomberg. The CBOE Equity Put/Call Ratio, which measures trading volume in put and call options (bearish and bullish bets respectively) recently hit its lowest level since July 2000. America’s S&P 500 reached a new-all time high last Friday, while early this week US markets were cheered by signs that congress could be set to approve a $908bn stimulus package.
The S&P 500’s recent high came on the back of employment data showing that America’s rapid jobs recovery slowed last month. Still, US unemployment hit nearly 15% earlier this year, but is now down to 6.7%.
Analysts forecast that S&P 500 earnings per share will rebound by 22% next year, following this year’s 15% fall, says Jon Sindreu in The Wall Street Journal. That looks “reasonable”; the year after the 2009 crash saw profit growth of 40%. The worry is for subsequent years. About 48% of S&P Composite 1500 companies are trading on a higher valuation than they did at the end of 2019. A V-shaped recovery next year is one thing; the idea that America Inc. will be more dynamic in 2022 than it was in 2019 looks much less sure.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
November’s euphoria reminded me of the dotcom boom, says Tom Stevenson in the Daily Telegraph. Europe’s markets gained 15% last month, giving a younger generation the closest thing to a “full-blooded melt-up” they have ever seen. Shares are high on a “cocktail of stimulants” from massive fiscal and monetary support to vaccine news. “It’s never a good sign” when there is almost no one questioning the bull story, but so contagious has the optimism become that even “Eeyore would be tempted to join in the fun”.
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Alex is an investment writer who has been contributing to MoneyWeek since 2015. He has been the magazine’s markets editor since 2019.
Alex has a passion for demystifying the often arcane world of finance for a general readership. While financial media tends to focus compulsively on the latest trend, the best opportunities can lie forgotten elsewhere.
He is especially interested in European equities – where his fluent French helps him to cover the continent’s largest bourse – and emerging markets, where his experience living in Beijing, and conversational Chinese, prove useful.
Hailing from Leeds, he studied Philosophy, Politics and Economics at the University of Oxford. He also holds a Master of Public Health from the University of Manchester.
-
Hargreaves Lansdown shakes up fees in biggest change in 10 years – what does it mean for you?Hargreaves Lansdown is lowering its headline fee from 0.45% to 0.35% – but not everyone will be happy with the new fee structure, it’s been suggested.
-
Michael Moritz: The richest Welshman to walk the EarthMichael Moritz started out as a journalist before catching the eye of a Silicon Valley titan. He finds Donald Trump to be “an absurd buffoon”
-
Three promising emerging-market stocks to diversify your portfolioOpinion Omar Negyal, portfolio manager, JPMorgan Global Emerging Markets Income Trust, highlights three emerging-market stocks where he’d put his money
-
Coface offers excess profit in an unloved sectorCoface is a world leader in trade-credit insurance with key competitive advantages in a niche market
-
Exciting opportunities in biotechBiotech firms should profit from the ‘patent cliff’, which will force big pharmaceutical companies to innovate or make acquisitions
-
How to invest in the new breed of payment providersUpstart payment providers are taking the world by storm. It’s time for investors to buy in, says Rupert Hargreaves
-
What turns a stock market crash into a financial crisis?Opinion Professor Linda Yueh's popular book on major stock market crashes misses key lessons, says Max King
-
How to add cryptocurrency to your portfolioA new listing shows how bitcoin might add value to a portfolio if cryptocurrency keeps gaining acceptance, says Cris Sholto Heaton
-
Profit from pest control with Rentokil InitialRentokil Initial is set for global expansion and offers strong sales growth
-
Three funds to buy for capital growth and global incomeOpinion Three investment trusts with potential for capital growth, selected by Adam Norris, co-portfolio manager of the CT Global Managed Portfolio Trust